Document:

Exhibit 4.1 -- Form of 5.25% Notes due 2013

 Exhibit 4.1 
 CUSIP NO. 579780 AG2 
 REGISTERED 
 PRINCIPAL AMOUNT
U.S.$250,000,000 
 No. 1 
 McCORMICK & COMPANY, INCORPORATED 
 U.S.$250,000,000 5.25% NOTES DUE 2013 
 If the registered owner of this Security (as indicated below) is The Depository Trust Company (the “Depository”) or a nominee of the
Depository, this Security is a Global Security and the following two legends apply: 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK) TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND SUCH CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL, SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

UNLESS AND UNTIL THIS CERTIFICATE IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN CERTIFICATED FORM, THIS CERTIFICATE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY
THE DEPOSITORY TO A NOMINEE THEREOF OR BY A NOMINEE THEREOF TO THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY OR BY THE DEPOSITORY OR ANY SUCH NOMINEE TO A SUCCESSOR OF THE DEPOSITORY OR A NOMINEE OF SUCH SUCCESSOR. 
 IF APPLICABLE, THE “TOTAL AMOUNT OF OID”, “YIELD TO MATURITY” AND “INITIAL ACCRUAL PERIOD OID” (COMPUTED UNDER THE APPROXIMATE METHOD)
BELOW WILL BE COMPLETED SOLELY FOR THE PURPOSES OF APPLYING THE FEDERAL INCOME TAX ORIGINAL ISSUE DISCOUNT (“OID”) RULES. 

			
	 ISSUE PRICE: $249,535,000
	  	OPTION TO ELECT REPAYMENT:
		  	 ̈ YES x NO
		
	ORIGINAL ISSUE DATE: September 3, 2008	  	OPTIONAL REPAYMENT DATES:
		
	STATED MATURITY DATE: September 1, 2013	  	MINIMUM DENOMINATION:
		  	  ̈ $1,000
 x Other: $2,000

		
	 SPECIFIED CURRENCY:
 United States Dollars:
 x YES  ̈ NO
	  	 ADDITIONAL AMOUNTS:
  
 DEFEASANCE: x YES  ̈ NO

		
	Foreign Currency:	  	COVENANT DEFEASANCE:
		  	x YES  ̈ NO
		
	EXCHANGE RATE AGENT:	  	TOTAL AMOUNT OF OID:
		
	 OPTION TO RECEIVE PAYMENTS IN SPECIFIED
CURRENCY OTHER THAN U.S. DOLLARS:  ̈ YES
 x NO
	  	YIELD TO MATURITY: 5.293%
		
		  	INITIAL ACCRUAL PERIOD OID:
		
	INTEREST RATE: 5.25%	  	SINKING FUND:
		
	PRINCIPAL FINANCIAL CENTER:	  	
		
	INTEREST PAYMENT DATES IF OTHER THAN
APRIL 15 AND OCTOBER 15: March 1 and September 1	  	
		
	REGULAR RECORD DATES IF OTHER THAN
APRIL 1 AND OCTOBER 1: February 15 and August 15	  	
		
	OPTIONAL REDEMPTION: x YES  ̈ NO	  	
		
	INITIAL REDEMPTION DATE:	  	
		
	INITIAL REDEMPTION PERCENTAGE:	  	
		
	ANNUAL REDEMPTION PERCENTAGE
REDUCTION:	  	

 OTHER/DIFFERENT PROVISIONS: 
 McCORMICK & COMPANY, INCORPORATED, a Maryland corporation (herein referred to as the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for value
received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of $250,000,000 on the Stated Maturity Date shown above (except to the extent redeemed or repaid prior to the Stated Maturity Date) and to pay
interest, if any, thereon at the Interest Rate shown above from the Original Issue Date shown above or from the most recent Interest Payment Date to which interest, if any, has been paid or duly provided for, semiannually on March 1 and
September 1 of each year (unless other Interest Payment Dates are shown on the face hereof) (each, an “Interest Payment Date”) until the principal hereof is paid or made available for payment and on the Stated Maturity Date, any
Redemption Date or Repayment Date (such terms are together hereinafter referred to as the “Maturity Date” with respect to the principal repayable on such date); provided, however, that any payment of principal (or premium, if any) or
interest, if any, to be made on any Interest Payment Date or on the Maturity Date that is not a Business Day (as defined below) shall be made on the next succeeding Business Day with the same force and effect as if made on such Interest Payment Date
or the Maturity Date, as the case may be, and no additional interest, if any, shall accrue on the amount so payable as a result of such delayed payment. For purposes of this Security, unless otherwise specified on the face 

  

 2 

 
hereof, “Business Day” means any day that is not a Saturday or Sunday and that is neither a legal holiday nor a day on which commercial banks are
authorized or required by law, regulation or executive order to close in The City of New York; provided, however, that, if the Specified Currency shown above is a foreign currency, such day is also not a day on which commercial banks are authorized
or required by law, regulation or executive order to close in the Principal Financial Center (as defined below) of the country issuing the Specified Currency (or, if the Specified Currency is the euro, such day is also a day on which the
Trans-European Automated Real-Time Gross Settlement Express Transfer (TARGET) System is open). “Principal Financial Center” means the capital city of the country issuing the Specified Currency except that with respect to United States
dollars, Australian dollars, Canadian dollars, Deutsche marks, Dutch guilders, South African rand and Swiss francs, the “Principal Financial Center” shall be The City of New York, Sydney and (solely in the case of the Specified Currency)
Melbourne, Toronto, Frankfurt, Amsterdam, Johannesburg and Zurich, respectively. 
 Any interest hereon will accrue from, and including, the
immediately preceding Interest Payment Date in respect of which interest, if any, has been paid or duly provided for (or from, and including, the Original Issue Date if no interest has been paid or duly provided for) to, but excluding, the
succeeding Interest Payment Date or the Maturity Date, as the case may be. The interest, if any, so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture and subject to certain exceptions
described herein (referred to on the reverse hereof), be paid to the person (the “Holder”) in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the February 15 or August 15
(whether or not a Business Day), as the case may be, next preceding such Interest Payment Date (unless other Regular Record Dates are specified on the face hereof) (each, a “Regular Record Date”); provided, however, that, if this Security
was issued between a Regular Record Date and the initial Interest Payment Date relating to such Regular Record Date, interest, if any, for the period beginning on the Original Issue Date and ending on such initial Interest Payment Date shall be paid
on the Interest Payment Date following the next succeeding Regular Record Date to the Holder hereof on such next succeeding Regular Record Date; and provided further that interest, if any, payable on the Maturity Date will be payable to the person
to whom the principal hereof shall be payable. Any such interest not so punctually paid or duly provided for on any Interest Payment Date other than the Maturity Date (“Defaulted Interest”) will forthwith cease to be payable to the Holder
on such Regular Record Date and may either be paid to the person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a special record date (the “Special Record Date”) for the
payment of such Defaulted Interest to be fixed by the Trustee (referred to on the reverse hereof), notice whereof shall be given to the Holder of this Security not less than ten days prior to such Special Record Date, or may be paid at any time in
any other lawful manner, all as more fully provided in the Indenture. 
 Unless otherwise specified above, all payments in respect of this
Security will be made in U.S. dollars regardless of the Specified Currency shown above unless the Holder hereof makes the election described below. If the Specified Currency shown above is other than U.S. dollars, the Exchange Rate Agent (referred
to on the reverse hereof) will arrange to convert any such amounts so payable in respect hereof into U.S. dollars in the manner described on the reverse hereof; provided, however, that the Holder hereof may, if so indicated above, elect to receive
all or any specified portion of any payment of principal, premium, if any, and/or interest, if any, in respect of this Security in such Specified Currency by delivery of a written request to the corporate trust office of the Trustee in The City of
New York, currently the office of the Trustee located at The Bank of New York Mellon, 101 Barclay Street, Floor 8W, New York, New York 10286, or at such other office in The City of New York, as the Company may determine, on or prior to the
applicable Regular Record Date or at least fifteen days prior to the Maturity Date, as the case may be. Such request may be in writing (mailed or hand delivered) or by cable, telex or other form of facsimile transmission. The Holder hereof may elect
to receive payment in such Specified Currency for all principal, premium, if any, and interest payments, if any, and need not file a separate election for each payment. Such election will remain in effect until revoked by written notice to the
Trustee, but written notice of any such revocation must be received by the Trustee on or prior to the applicable Regular Record Date or at least fifteen days prior to the Maturity Date, as the case may be. 
 Notwithstanding the foregoing, if the Company determines that the Specified Currency is not available for making payments in respect hereof due to the
imposition of exchange controls or other circumstances beyond the Company’s control, or is no longer used by the government of the country issuing such currency or for the settlement of transactions by public institutions of or within the
international banking community, then the Holder hereof may not so elect to receive payments in the Specified Currency and any such outstanding election shall be automatically suspended, until the Company determines that the Specified Currency is
again available for making such payments. Any payment made under such circumstances in U.S. dollars where the required payment is in a Specified Currency will not constitute a default under the Indenture. 
 In the event of an official redenomination of the Specified Currency, the obligations of the Company with respect to payments on this Security, in all
cases, shall be deemed immediately following such redenomination to provide for payment of that amount of redenominated currency representing the amount of such obligations immediately before such redenomination. In no event shall any adjustment be
made to any amount payable hereunder as a result of any change in the value of the Specified Currency shown above relative to any other currency due solely to fluctuations in exchange rates. 
  

 3 

 Until this Security is paid in full or payment therefor in full is duly provided for, the Company will at
all times maintain a Paying Agent (which Paying Agent may be the Trustee) in The City of New York, currently the office of the Trustee located at The Bank of New York Mellon, 101 Barclay Street, Floor 8W, New York, New York 10286, or at such other
office in The City of New York, as the Company may determine (which, unless otherwise specified above, shall be the “Place of Payment”). The Company has initially appointed The Bank of New York Mellon, at its office in The City of New
York, currently the office of the Trustee located at The Bank of New York Mellon, 101 Barclay Street, Floor 8W, New York, New York 10286, or at such other office in The City of New York, as the Company may determine as Paying Agent. 
 Unless otherwise shown above, payment of interest on this Security (other than on the Maturity Date) will be made by check mailed to the registered
address of the Holder hereof as of the Regular Record Date; provided, however, that, if (i) the Specified Currency is U.S. dollars and this is a Global Security (as defined on the reverse hereof) or (ii) the Specified Currency is a Foreign
Currency, and the Holder has elected to receive payments in such Specified Currency as provided for above, such interest payments will be made by transfer of immediately available funds, but only if appropriate wire transfer instructions have been
received in writing by the Trustee on or prior to the applicable Regular Record Date. Simultaneously with any election by the Holder hereof to receive payments in respect hereof in the Specified Currency (if other than U.S. dollars), such Holder may
provide appropriate wire transfer instructions to the Trustee, and all such payments will be made in immediately available funds to an account maintained by the payee with a bank, but only if such bank has appropriate facilities therefor. Unless
otherwise specified above, the principal hereof (and premium, if any) and interest, if any, hereon payable on the Maturity Date will be paid in immediately available funds upon surrender of this Security at the office of the Trustee maintained for
that purpose in The City of New York, currently the office of the Trustee located at The Bank of New York Mellon, 101 Barclay Street, Floor 8W, New York, New York 10286, or at such other office in The City of New York, as the Company may determine.
The Company will pay any administrative costs imposed by banks in making payments in immediately available funds but, except as otherwise provided under Additional Amounts above, any tax, assessment or governmental charge imposed upon payments will
be borne by the Holders of the Securities in respect of which such payments are made. 
 Interest on this Security, if any, will be computed
on the basis of a 360-day year of twelve 30-day months. 
 REFERENCE IS HEREBY MADE TO THE FURTHER PROVISIONS OF THIS SECURITY SET FORTH ON
THE REVERSE HEREOF, WHICH FURTHER PROVISIONS SHALL FOR ALL PURPOSES HAVE THE SAME EFFECT AS IF SET FORTH AT THIS PLACE. 
 Unless the
certificate of authentication hereon has been executed by the Trustee by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
  

 4 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its facsimile
corporate seal. 
  

			
	McCORMICK & COMPANY, INCORPORATED
		
	By:	 	 
		 	 Name: Paul C. Beard
 Title:   Senior Vice
President Finance and Treasurer

  

			
	
		
	By:	 	 
		 	 Name: Gordon M. Stetz, Jr.
 Title:
  Executive Vice President and Chief Financial Officer

  
  

			
	[CORPORATE SEAL]
		
	Attest:	 	 
		 	 Name: W. Geoffrey Carpenter
 Title:
  Associate General Counsel and
   Assistant Secretary

  
 Dated: September 3, 2008 
  

 5 

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
  
  

			
	This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture
	
	 The Bank of New York Mellon,
     as Trustee

		
	By:	 	 
		 	Authorized Signatory

  
 Dated: September 3, 2008

  

 6 

 McCORMICK & COMPANY, INCORPORATED 
 U.S. $250,000,000 5.25% NOTE DUE 2013 
 Section 1. General. This
Security is one of a duly authorized issue of securities (herein called the “Securities”) of the Company, issued and to be issued in one or more series under that certain Indenture, dated as of December 7, 2007, as it may be
supplemented from time to time (herein called the “Indenture”), between the Company and The Bank of New York Mellon (formerly known as The Bank of New York), Trustee (herein called the “Trustee”, which term includes any successor
trustee under the Indenture with respect to a series of which this Security is a part), to which Indenture and all indentures supplemental thereto, reference is hereby made for a statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities are, and are to be, authenticated and delivered. 
 Section 2. Payments. If the Specified Currency is other than U.S. dollars and the Holder hereof fails to elect payment in such Specified
Currency in accordance with the procedures set forth on the face hereof, the amount of U.S. dollar payments to be made in respect hereof will be determined by the Exchange Rate Agent specified on the face hereof or a successor thereto (the
“Exchange Rate Agent”) based on the highest bid quotation in The City of New York at approximately 11:00 A.M., New York City time, on the second Business Day preceding the applicable payment date received by the Exchange Rate Agent
from three recognized foreign exchange dealers (one of whom may be the Exchange Rate Agent) selected by the Exchange Rate Agent and approved by the Company for the purchase by the quoting dealer of the Specified Currency for U.S. dollars for
settlement on such payment date in the aggregate amount of the Specified Currency payable to all holders of Securities scheduled to receive U.S. dollar payments and at which the applicable dealer commits to execute a contract. If three such bid
quotations are not available, payments will be made in the Specified Currency. 
 If the Specified Currency is other than U.S. dollars and
the Holder hereof has elected payment in such Specified Currency in accordance with the procedures set forth on the face hereof and the Specified Currency is not available due to the imposition of exchange controls or to other circumstances beyond
the Company’s control, the Company will be entitled to satisfy its obligations to the Holder of this Security by making such payment in U.S. dollars on the basis of the noon buying rate in The City of New York for cable transfers of such
Specified Currency as certified for customs purposes (or, if not so certified, as otherwise determined) by the Federal Reserve Bank of New York (the “Market Exchange Rate”) as computed by the Exchange Rate Agent on the second Business Day
prior to the applicable payment date or, if the Market Exchange Rate is then not available, on the basis of the most recently available Market Exchange Rate or as otherwise indicated above. Any payment made under such circumstances in U.S. dollars
where the required payment is in a Specified Currency will not constitute a default under the Indenture. 
 All determinations referred to
above made by the Exchange Rate Agent shall be at its sole discretion (except to the extent expressly provided that any determination is subject to approval by the Company) and, in the absence of manifest error, shall be conclusive for all purposes
and binding on the Holder of this Security, and the Exchange Rate Agent shall have no liability therefor. 
 All currency exchange costs will
be borne by the Company. 
 References herein to “U.S. dollars” or “U.S. $” or “$” are to the currency of the
United States of America. 
 Section 3. Redemption. If so specified on the face hereof, the Company may at its option redeem this
Security in whole or from time to time in part in increments of $1,000 (provided that any remaining principal amount of this Security shall not be less than the Minimum Denomination specified on the face hereof) at a Redemption Price equal to the
greater of (i) 100% of the principal amount hereof and (ii) the sum of the present values of the remaining scheduled payments of principal and interest thereon (exclusive of interest accrued to the Redemption Date) discounted to the
Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 35 basis points, plus, in either case, accrued and unpaid interest thereon to the Redemption Date. The Company may exercise
such option by causing the Trustee to mail a notice of such redemption at least 30 but not more than 60 days prior to the Redemption Date. In the event of redemption of this Security in part only, a new Security or Securities for the unredeemed
portion hereof shall be issued in the name of the Holder hereof upon the cancellation hereof. If less than all of the Securities with like tenor and terms to this Security are to be redeemed, the Securities to be redeemed shall be selected by the
Trustee by such method as the Trustee shall deem fair and appropriate. However, if less than all the Securities of the series with differing tenor and terms to this Security are to be redeemed, then the Company in its sole discretion shall select
the particular Securities to be redeemed and shall notify the Trustee in writing thereof at least 45 days prior to the relevant Redemption Date. 
  

 7 

 For purposes of the foregoing: 
 “Treasury Rate” means, with respect to any Redemption Date, (a) the yield, under the heading which represents the average for the
immediately preceding week, appearing in the most recently published statistical release published by the Board of Governors of the Federal Reserve System designated as “Statistical Release H.15(519)” or any successor publication which is
published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption “Treasury Constant Maturities,” for
the maturity corresponding to the Comparable Treasury Issue (if no maturity is within three months before or after the maturity date, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue shall be
determined and the Treasury Rate shall be interpolated or extrapolated from such yields on a straight line basis, rounding to the nearest month), or (b) if such release (or any successor release) is not published during the week preceding the
calculation date or does not contain such yields, the rate per year equal to the semiannual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its
principal amount) equal to the Comparable Treasury Price for such Redemption Date. The Treasury Rate shall be calculated on the third business day preceding the Redemption Date. 
 “Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker as having an actual or
interpolated maturity comparable to the remaining term of the notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of a
comparable maturity to the remaining term of such notes. 
 “Independent Investment Banker” means Banc of America Securities LLC or
BNP Paribas Securities Corp. or either of their respective successors, or if both such firms are unwilling or unable to select the Comparable Treasury Issue, an independent investment banking institution of national standing appointed by the Trustee
after consultation with us. 
 “Comparable Treasury Price” means, with respect to any Redemption Date, (1) the average of the
Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (2) if the Trustee obtains fewer than four such Reference Treasury Dealer Quotations, the
average of all such quotations. 
 “Reference Treasury Dealer” means (1) Banc of America Securities LLC or its affiliates
which are primary U.S. Government securities dealers in The City of New York (a “Primary Treasury Dealer”), and its successors, and (2) three other Primary Treasury Dealers selected by us; provided, however, that if any of the
foregoing or their affiliates shall cease to be a Primary Treasury Dealer, we shall substitute therefor another Primary Treasury Dealer. 
 “Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue
(expressed in each case as a percentage of its principal amount) quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m., New York time, on the third business day preceding such Redemption Date. 
 Section 4. Repayment. If so specified on the face hereof, this Security shall be repayable prior to the Stated Maturity Date at the option of
the Holder on each applicable Optional Repayment Date shown on the face hereof at a repayment price equal to 100% of the principal amount to be repaid, together with accrued interest, if any, to the Repayment Date. In order for this Security to be
repaid, the Trustee must receive at least 30 but not more than 45 days prior to an Optional Repayment Date, this Security with the form attached hereto entitled “Option to Elect Repayment” duly completed. Any tender of this Security for
repayment shall be irrevocable. The repayment option may be exercised by the Holder of this Security in whole or in part in increments of $1,000 (provided that any remaining principal amount of this Security shall not be less than the Minimum
Denomination specified on the face hereof). Upon any partial repayment, this Security shall be canceled and a new Security or Securities for the remaining principal amount hereof shall be issued in the name of the Holder of this Security.

 Section 5. Change of Control Redemption. If a Change of Control Triggering Event, as defined below, occurs, each Holder of this
Security will have the right to require the Company to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of this Security pursuant to the offer described below (the “Change of Control Offer”)
on the terms set forth herein. In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the aggregate principal amount of this Security repurchased plus accrued and unpaid interest, if any, on the
Security repurchased, to the date of purchase (the “Change of Control Payment”). Within 30 days following any Change of Control Triggering Event, the Company will send notice of such Change of Control Offer (the “Change of Control
Offer Notice”) by first-class mail, with a copy to the Trustee, to each Holder of this Security to the address of such Holder appearing in the 

  

 8 

 
security register or otherwise in accordance with the procedures of The Depository Trust Company (the “Depositary”) with a copy to the Trustee,
with the following information: (a) that the Change of Control Offer is being made pursuant to the provisions of the Indenture and that each Security properly tendered pursuant to such Change of Control Offer will be accepted for payment by the
Company; (b) the date of the Change of Control Triggering Event; (c) the date, which will be no earlier than 30 days and no later than 60 days after the date the Change of Control Offer Notice is mailed, by which the Company must purchase
the Security (the “Change of Control Payment Date”); (d) the price that the Company must pay for the Security the Company is obligated to purchase; (e) the name and address of the Trustee; (f) that any Security not properly
tendered will remain outstanding and continue to accrue interest; (g) that unless the Company defaults in the payment of the Change of Control Payment, each Security accepted for payment pursuant to the Change of Control Offer will cease to
accrue interest on the Change of Control Payment Date; (h) the procedures for surrendering the Security for payment; and (i) the procedures by which a Holder may withdraw such a tender after it is given. 
 The Company must comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent
those laws and regulations are applicable in connection with the purchase of this Security as a result of a Change of Control Triggering Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of
Control provisions of this Security, the Company will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control provisions of this Security by virtue
of such conflicts. 
 On the Change of Control Payment Date, the Company will be required, to the extent lawful, to: (a) accept for
payment all or a part of this Security properly tendered pursuant to the Change of Control Offer; (b) deposit with the paying agent an amount equal to the Change of Control Payment in respect of all or the part of this Security properly
tendered; and (c) deliver or cause to be delivered to the Trustee each Security properly accepted. 
 For purposes of the foregoing:

 “Below Investment Grade Rating Event” means this Security is rated below an Investment Grade Rating by each of the Rating
Agencies on any date from the date of the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be
extended so long as the rating of this Security is under publicly announced consideration for possible downgrade by either of the Rating Agencies). 
 “Change of Control” means the occurrence of any of the following: (1) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related
transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries taken as a whole to any person (as such term is used in Section 13(d) of the Exchange Act) other than the Company or one of its
subsidiaries; (2) the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any person (as such term is used in Section 13(d) of the Exchange Act) becomes the beneficial
owner, directly or indirectly, of more than 50% of the then outstanding number of shares of the Company’s voting stock; or (3) the first day on which a majority of the members of the Company’s Board of Directors are not Continuing
Directors. 
 “Change of Control Triggering Event” means the occurrence of both a Change of Control and a Below Investment Grade
Rating Event. 
 “Continuing Directors” means, as of any date of determination, any member of the Company’s Board of Directors
who (1) was a member of such Board of Directors on the date of the issuance of this Security; or (2) was nominated for election or elected to such Board of Directors with the approval of a majority of the Continuing Directors who the were
members of such Board of Directors at the time of such nomination or election (either by a specific vote or by approval of the Company’s proxy statement in which such member was named as a nominee for election as a director, without objection
to such nomination). 
 “Investment Grade Rating” means a rating equal to or higher than Baa3 (or the equivalent) by Moody’s
and BBB- (or the equivalent) by S&P. 
 “Moody’s” means Moody’s Investors Service, Inc. 
 “Rating Agencies” means (1) each of Moody’s and S&P; and (2) if either of Moody’s or S&P ceases to rate this
Security or fails to make a rating of this Security publicly available for reasons outside of the Company’s control, a “nationally recognized statistical rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the
Exchange Act, selected by 

  

 9 

 
the Company (as certified by a resolution of the Company’s Board of Directors) as a replacement agency for Moody’s or S&P, or both of them, as
the case may be. 
 “S&P” means Standard and Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc.

 Section 6. Discount Securities. If this Security (such a Security being referred to as a “Discount Security”)
(a) has been issued at an Original Issue Price lower, by more than a de minimis amount (as determined under United States federal income tax rules applicable to original issue discount instruments), than the stated redemption price at
maturity (as defined below) hereof and (b) would be considered an original issue discount security for United States federal income tax purposes, then the amount payable on this Security in the event of redemption by the Company, repayment at
the option of the Holder or acceleration of the maturity hereof, in lieu of the principal amount due at the Stated Maturity Date hereof, shall be the Amortized Face Amount (as defined below) of this Security as of the date of such redemption,
repayment or acceleration. The “Amortized Face Amount” of this Security shall be the amount equal to the sum of (a) the Issue Price (as set forth on the face hereof) plus (b) the aggregate of the portions of the original issue
discount (the excess of the amounts considered as part of the “stated redemption price at maturity” of this Security within the meaning of Section 1273(a)(2) of the Internal Revenue Code of 1986, as amended (the
“Code”), whether denominated as principal or interest, over the Issue Price of this Security) which shall theretofore have accrued pursuant to Section 1272 of the Code (without regard to Section 1272(a)(7) of the Code) from
the date of issue of this Security to the date of determination, minus (c) any amount considered as part of the “stated redemption price at maturity” of this Security which has been paid on this Security from the date of issue to the
date of determination. 
 Section 7. Modification and Waivers; Obligation of the Company Absolute. The Indenture permits, with
certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series. Such amendment may be effected under the Indenture at any
time by the Company and the Trustee with the consent of the Holders of not less than a majority in principal amount of Outstanding Securities of each series affected thereby. The Indenture also contains provisions permitting the Holders of not less
than a majority in principal amount of the Outstanding Securities of any series, on behalf of the Holders of all Outstanding Securities of such series, to waive compliance by the Company with certain provisions of the Indenture. Provisions in the
Indenture also permit the Holders of not less than a majority in principal amount of all Outstanding Securities of any series to waive on behalf of all of the Holders of Securities of such series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon the Holder of this Security and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in
lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 The Securities are unsecured and rank pari
passu with all other unsecured and unsubordinated indebtedness of the Company. 
 No reference herein to the Indenture and no provision of
this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of (and premium, if any) and interest, if any, on this Security at the times, place and rate, and in the
Specified Currency herein prescribed, except as set forth in Section 2 hereof. 
 Section 8. Defeasance and Covenant
Defeasance. The Indenture contains provisions for defeasance at any time of (a) the entire indebtedness of the Company on this Security and (b) certain restrictive covenants and the related defaults and Events of Default, upon compliance
by the Company with certain conditions set forth therein, which provisions apply to this Security, unless otherwise specified on the face hereof. 
 Section 9. Minimum Denomination; Authorized Denominations. Unless otherwise provided on the face hereof, this Security is issuable only in registered form without coupons in denominations of $2,000 or any amount in excess
thereof which is an integral multiple of $1,000. If this Security is denominated in a Specified Currency other than U.S. dollars or is a Discount Security, this Security shall be issuable in the denominations set forth on the face hereof.

 Section 10. Registration of Transfer. As provided in the Indenture and subject to certain limitations herein and therein set
forth, the transfer of this Security is registrable in the Security Register upon surrender of this Security for registration of transfer at a Place of Payment for the series of Securities of which this Security forms a part, duly endorsed by, or
accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of this series,
of like authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
 If the registered owner of this Security is the Depository (such a Security being referred to as a “Global Security”), and (i) the Depository is at any time unwilling or unable to continue as depository and a successor
depository is not appointed by the 

  

 10 

 
Company within 90 days following notice to the Company or (ii) an Event of Default occurs, the Company will issue Securities in certificated form in
exchange for this Global Security. In addition, the Company may at any time, and in its sole discretion, determine not to have Securities represented by a Global Security and, in such event, will issue Securities in certificated form in exchange in
whole for this Global Security. In any exchange pursuant to this paragraph, the Company will execute, and the Trustee, upon receipt of a Company Order for the authentication and delivery of individual Securities of this series in exchange for this
Global Security, will authenticate and deliver individual Securities of this series in certificated form in an aggregate principal amount equal to the principal amount of this Global Security in exchange herefor. Securities issued in exchange for
this Global Security pursuant to this paragraph shall be registered in such names and in such authorized denominations as the Depository, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee.
None of the Company, the Trustee, any Paying Agent or the Security Registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in this Global Security or
for maintaining, supervising or reviewing any records relating to such beneficial ownership interests. For purposes of the Indenture, this Global Security constitutes a Security issued in permanent global form. Securities so issued in certificated
form will be issued in denominations of $2,000 (or such other denomination as shall be specified on the face hereof) or any amount in excess thereof which is an integral multiple of $1,000 and will be issued in registered form only, without coupons.

 As provided in the Indenture and subject to certain limitations therein and herein set forth, this Security is exchangeable for a like
aggregate principal amount of Securities of this series of different authorized denominations but otherwise having the same terms and conditions, as requested by the Holder hereof surrendering the same. 
 No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any
tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for registration of transfer,
the Company, the Trustee and any agent of the Company or the Trustee may treat the Holder as the owner hereof for all purposes, whether or not this Security be overdue, and none of the Company, the Trustee nor any such agent shall be affected by
notice to the contrary. 
 Section 11. Events of Default. If an Event of Default with respect to the Securities of the series of
which this Security forms a part shall have occurred and be continuing, the principal of this Security may be declared due and payable in the manner and with the effect provided in the Indenture. 
 Section 12. Defined Terms. All terms used in this Security which are defined in the Indenture and are not otherwise defined herein shall have
the meanings assigned to them in the Indenture. 
 Section 13. Governing Law. Unless otherwise specified on the face hereof, this
Security shall be governed by and construed in accordance with the law of the State of New York. 
 *   *   *  
*   * 
  

 11 

 ABBREVIATIONS 
 The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

					
	TEN COM	 	–	  	as tenants in common
	TEN ENT	 	–	  	as tenants by the entireties
	JT TEN	 	–	  	as joint tenants with right of survivorship and not as tenants in common
			
	UNIF GIFT MIN ACT	 	–	  	CUSTODIAN
		 		  	 
		 		  	 (Cust.)                                       
     (Minor)
  
 UNDER UNIFORM GIFTS
TO MINORS ACT

		 		  	 
		 		  	(State)

 Additional abbreviations may also be used though not in the above list. 
  
  
 FOR VALUE RECEIVED, the undersigned 
 hereby sell(s), assign(s) and transfer(s) unto

  

					
	PLEASE INSERT SOCIAL SECURITY OR
OTHER
IDENTIFYING NUMBER OF ASSIGNEE	 	 
	  	 	  	 	 
	
	  
	 Please print or type name and address, including zip code of assignee

	
	  
	 the within Security of McCORMICK & COMPANY, INCORPORATED and all rights thereunder and does hereby irrevocably constitute and
appoint
  

	
	 
	  
 Attorney to transfer the said Security on the books of the
within-named Company, with full power of substitution in the premises.

			
	  
 Dated
  
	 		 	
	SIGNATURE GUARANTEED:	 	  	 	 
	  	 	  
	  	 	  
		 	NOTICE: The signature to this assignment must correspond with the name as it appears upon the face of the Security in every particular, without alteration or enlargement or any
change whatsoever.

  

 12Amended and Restated Main Agreement

 EXHIBIT 10.1 
 AMENDED AND RESTATED 
 MAIN AGREEMENT 
 This Amended and Restated Main Agreement (this “Agreement”), dated as of September 3, 2008 (the “Effective Date”),
is between DS Pharmacy, Inc., a Delaware corporation, on its behalf and on behalf of its parent corporation and Affiliates (“drugstore.com”), and Rite Aid Hdqtrs. Corp., a Delaware corporation, on its behalf as well as on behalf of
its parent corporation and Affiliates (“Rite Aid”). Upon the execution of this Agreement, the Main Agreement dated June 17, 1999 is amended and restated in its entirety as set forth herein. 
 RECITALS 
  

	 	A.	Rite Aid is a leading drugstore in the United States with approximately 5,000 stores. 

  

	 	B.	drugstore.com is a leading online drugstore. 

 AGREEMENT

 In consideration of the agreements, covenants and conditions set forth herein, intending to be legally bound, the parties hereto agree
as follows: 
 Section 1. Definitions 
 Whenever used in this Agreement with initial letters capitalized, the following terms will have the following specified meanings: 
 “Affiliate” means, with respect to a party, any Person that, directly or indirectly, Controls, or is Controlled by, or is under common Control with, such party. 
 “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of
a Person, whether by contract or through the ownership of voting securities, including the ownership of more than fifty percent (50%) of the equity, partnership or similar interest in such Person. 
 “Derivative” means (a) any enhancement, improvement or modification or (b) any “derivative work” (as such term is
defined in the U.S. Copyright Act, as amended from time to time). 

 “Drugstore Chain Competitor” means any Third Party that Controls 10 or more Offline
Retail Drugstores, whether or not all such stores operate under the same name or Trademark, whose business substantially consists of the sale of Pharmaceutical Products to retail customers. For the avoidance of doubt, the term does not include
supermarket chains or mass retail merchandisers (such as Wal-Mart or Target). 
 “drugstore.com IPR” means (i) any and
all IPR owned or licensable without cost to drugstore.com by drugstore.com or any entity that it Controls, and (ii) all Rite Aid Technology Derivatives and Derivatives of Rite Aid Technology Derivatives made by or at the direction of
drugstore.com or any entity that it Controls. 
 “drugstore.com Site” means the site currently located at www.drugstore.com
(and any successor site, Mirror site or sites of any entity Controlled by drugstore.com). 
 “including” or
“included,” when used herein, shall be deemed to be followed by the words “without limitation.” 
 “Internet” means the Internet or the World Wide Web (or any successor or other online network including those using delivery over television, cable, set top boxes, intranets, extranets and personal digital assistants (but
not including using any personal digital assistant or other device as a telephone)). 
 “IPR” means any copyright,
Trademark, patent, trade secret, moral right or other intellectual property or proprietary right of any kind (including applications therefor and, in the case of patents, any continuation or divisional patent applications claiming priority thereto),
whether arising under the laws of the United States or any other nation, state or jurisdiction (including any foreign equivalents thereto). 
 “LPU” means a service through which customers are able to place orders for Pharmaceutical Products through the Internet for pick up at a local offline Rite Aid pharmacy. 
 “LPU Inventory” means the prescription inventory purchases paid by drugstore.com to Rite Aid for LPU prescription orders awaiting pick
up as of the close of business on a date to be determined by the parties. For the avoidance of any doubt, LPU Inventory does not include any prescription inventory that has been previously charged to but not yet paid by drugstore.com to Rite Aid.

 “Mirror site” means an Internet site that (i) contains the exact form and content of a site, (ii) is located at
a geographic location distinct from a site and (iii) is created for the purpose of improving the performance of and accessibility to a site. 
 “New LPU Prescription” means each new prescription in an LPU order placed by a customer who has not placed an LPU order during the 12 months prior to the date the customer places the order in question (a “New LPU
Customer”), provided, however, in 

  

 1 

 
no event shall a prescription that is paid for in whole or in part by any state or federally funded program, including but not limited to Medicaid, Medicare
Part D, PACE, PAAD, EPIC, be considered a New LPU Prescription. For the avoidance of doubt, (i) a refill of a previous prescription does not constitute a New LPU Order, and (ii) as an example, an LPU order placed by a New LPU Customer for
three (3) new prescription medications would constitute three (3) New LPU Prescriptions. 
 “Offline Retail
Drugstore” means any Third Party physical (i.e., bricks-and-mortar) drugstore that operates within it a licensed pharmacy for dispensing Pharmaceutical Products to retail customers. 
 “Person” means any individual, corporation, partnership, limited liability company, trust, association or other entity or organization,
including any governmental or political subdivision or any agency or instrumentality thereof. 
 “Pharmaceutical Products”
means any product that under law may not be dispensed except pursuant to a prescription dispensed by a licensed professional. 
 “Pharmacy Services Page” means the first page a user sees on the drugstore.com Site after clicking on the pharmacy tab, currently located at www.drugstore.com/pharmacy. 
 “Rite Aid IPR” means any and all IPR owned or licensable without cost to Ride Aid by Rite Aid or any entity that it Controls, including
the Rite Aid Technology and the Rite Aid Technology Derivatives and Derivatives of Rite Aid Technology Derivatives made by or at the direction of Rite Aid or any entity that it Controls. 
 “Rite Aid Site” means the site currently located at www.riteaid.com (and any successor site, Mirror site or sites of any entity
Controlled by Rite Aid). 
 “Rite Aid Technology” means the software (in both source and object code forms) set forth on
Exhibit A, to the extent owned or licensable (without cost to Rite Aid) by Rite Aid during the Term. 
 “Rite Aid Technology
Derivative” means a Derivative of any Rite Aid Technology. 
 “Rite Aid Trademarks” means the Trademarks owned by
Rite Aid set forth on Exhibit B. 
 “Term” means the period commencing on the Effective Date and ending on the second
anniversary of such date, subject to extension in accordance with Section 11.5. 
 “Third Party” means any Person that
is not a party hereto or an Affiliate of a party hereto. 
  

 2 

 “Trademark(s)” means all common law or registered trademarks, logos, service marks,
trade names, Internet domain names and trade dress rights and similar or related rights arising under any of the laws of the United States or any other country or jurisdiction, whether now existing or hereafter adopted or acquired. 
 Section 2. Local Pick-up 
 2.1
drugstore.com and Rite Aid will work cooperatively and in good faith to effect a seamless transition of the LPU service developed, hosted, operated and maintained by drugstore.com to an LPU service maintained by Rite Aid on the Rite Aid Site;
provided, however, that drugstore.com will continue to host, operate and maintain the LPU service functionality on the drugstore.com Site until June 17, 2009 or any earlier date that Rite Aid identifies as an appropriate transition date for the
LPU service (the date of such transition is referred to as the “LPU Transition Date”). Until the LPU Transition Date, drugstore.com will not alter or change the direct interface technology components related to the LPU service
without Rite Aid’s prior approval, nor will it be required by Rite Aid to alter or change the direct interface technology components.  
 2.2 Notwithstanding the earlier transition of LPU service functionality pursuant to Section 2.1, drugstore.com shall continue to maintain during the Term of this Agreement (subject to earlier termination as provided in
Section 5.1) the LPU link on the Pharmacy Services Page with the same placement and prominence as the existing offering as reflected in Schedule 2.1. The link shall directly link customers to the LPU service maintained on the Rite Aid Site. So
long as the LPU link to the Rite Aid Site is maintained on the drugstore.com Site, the Rite Aid Site shall have a link back to the drugstore.com Site for customers to return to the drugstore.com Site. 
 2.3 In consideration of the transfer of LPU services from drugstore.com to Rite Aid and, subject to Sections 10 and 11, provided that
drugstore.com does not intentionally discontinue its hosting, operation and maintenance of the LPU service functionality prior to the LPU Transition Date, Rite Aid agrees to pay drugstore.com nine million nine hundred ten thousand dollars
($9,910,000) as follows: 
  

				
	 Due Date
	  	Amount Due
	 9/17/08
	  	$	991,000.00
	 10/17/08
	  	$	991,000.00
	 11/17/08
	  	$	991,000.00
	 12/17/08
	  	$	991,000.00
	 1/19/09
	  	$	991,000.00
	 2/17/09
	  	$	991,000.00
	 3/17/09
	  	$	991,000.00
	 4/17/09
	  	$	991,000.00
	 5/18/09
	  	$	991,000.00
	 6/17/09
	  	$	991,000.00

  

 3 

 Rite Aid will wire each payment to drugstore.com’s identified financial institution. In the event that Rite Aid is
late with any monthly payment it will pay a late payment fee equal to one percent (1%) per month pro-rated for each partial month. 
 2.4 The parties further agree that Rite Aid will acquire from drugstore.com the full balance of drugstore.com’s LPU Inventory as of the Effective Date. The parties agree to cooperatively determine: (i) the full balance and
identity of drugstore.com’s LPU Inventory and the methodology to determine the economic value of the LPU Inventory (the “LPU Inventory Value”); and (ii) the LPU orders that are in will call (and not picked up) as of the
Effective Date and the identity and other necessary pharmacy and contact information of LPU orders for such period prior to the Effective Date as reasonably requested by Rite Aid in connection with the transition of the LPU service. Rite Aid will
credit the LPU Inventory Value on the first invoice issued to drugstore.com following the Effective Date. 
 2.5 Commencing on the
Effective Date and throughout the term of this Agreement, Rite Aid will pay drugstore.com a fee as set forth in Schedule 2.5(the “LPU Fee”) for each New LPU Prescription purchased through the existing drugstore.com Site. 

 

	 	2.5.1	drugstore.com will provide Rite Aid with the identity and other necessary information (including but not limited to email addresses) associated with each New LPU
Prescription, as well as a copy of each New LPU Prescription, on a monthly basis in order to confirm such New LPU Prescription. 

  

	 	2.5.2	Rite Aid will pay the LPU Fees no later than thirty (30) days from its receipt of the appropriate information from drugstore.com. If such payment date falls on a weekend
or on any weekday on which banks are closed, payment shall be due on the business day immediately following such payment date. All payments made by Rite Aid pursuant to this Section 2.4 shall be made, in immediately available funds, by
electronic fund transfer or such other means reasonably acceptable to both parties. 

  

	 	2.5.3	Late Payments. For any late payment, a late fee shall be applicable in the amount of one percent for each whole month after the payment was due, prorated for any
partial month. 

 2.6 For the avoidance of doubt, nothing herein should be construed as amending the terms of the Main
Agreement with respect to payments due from Rite Aid to drugstore.com under the Main Agreement for LPU orders placed prior to the Effective Date. 
  

 4 

 2.7 Upon the Effective Date and thereafter: 
  

	 	2.7.1 	Rite Aid will be the exclusive owner of every LPU prescription presented through the Rite Aid Site and every LPU prescription presented through the drugstore.com Site.

  

	 	2.7.2 	Rite Aid will be the exclusive owner of all customer data related to every LPU prescription presented through the Rite Aid Site and all customer data related to every LPU
prescription presented through the drugstore.com Site. 

  

	 	2.7.3 	Rite Aid will be the exclusive owner of every new and refilled LPU prescription as well as all associated revenue and margin. 

 Section 3. Pharmacy Information 
 Subject to
customer and any other required consents, pending the LPU transition contemplated in Section 2, the parties will (i) share insurance and drug profile information related to customers serviced under this Agreement (“Customer
Information”) in order to pre-populate customer profiles on the drugstore.com Site and (ii) systematically and promptly update each other’s shared customer profiles to reflect any new Customer Information acquired with respect to
any such profiles. drugstore.com shall neither transmit nor disclose (except for purposes of satisfying its obligations under this Agreement) any Customer Information to Third Parties, nor use such Customer Information to market to such customers,
provided, however, that nothing in this Agreement will limit drugstore.com’s right to use or transmit information obtained from customers of the drugstore.com Site other than in connection with the LPU services. 
 Section 4. Exclusivity 
 4.1 drugstore.com
will not offer, will not permit its Affiliates or any entity that it Controls to offer, and will not contract with any Third Party to offer on the drugstore.com Site, any competitive service to the LPU service (i) through June 17, 2009,
and (ii) thereafter for the remaining Term of this Agreement so long as it is not required by any Third Party purchaser of drugstore.com’s mail-order pharmacy business to offer such a service as a condition to such purchase. For the
avoidance of doubt, nothing in this Agreement shall be construed to prohibit drugstore.com or its Affiliates from offering services similar to the LPU service for products other than Pharmaceutical Products, including without limitation, contact
lenses, vitamins or over-the-counter products. 
 4.2 The provisions of this Section 4 will not be applicable to
drugstore.com’s operations outside the United States and shall not limit drugstore.com’s ability to partner with and promote an Offline Retail Drugstore that has no Offline Retail Drugstore presence in the United States. In the event any
such non-U.S. partner subsequently 

  

 5 

 
develops any presence in the United States, including by purchasing an Offline Retail Drugstore in the United States, drugstore.com shall forthwith take all
actions necessary to place it in compliance with this Agreement. 
 Section 5. Pharmacy Services Page 
 5.1 drugstore.com shall maintain an LPU link (which shall be directly linked to the Rite Aid Site) on the Pharmacy Services Page or elsewhere
(which shall be subject to Rite Aid’s prior approval) on the drugstore.com Site and any promotion by drugstore.com in any other media of the LPU service shall be prominently branded with a Rite Aid Trademark. The Rite Aid Trademark shall be
maintained on the Pharmacy Services Page with the same placement and prominence as currently existing under the Main Agreement as reflected in Schedule 2.1. Upon request by drugstore.com at any time following June 17, 2009, subject to
Section 4.1, the parties agree to meet and confer regarding early termination of drugstore.com’s maintenance of the LPU link on the Pharmacy Services Page in the event that there is not a sufficient number of customers (based upon the
reasonable determination of the parties) utilizing the link from the drugstore.com Site to the LPU service maintained on the Rite Aid Site. 
 5.2 Rite Aid shall not knowingly publish on the Rite Aid Site, and drugstore.com shall not knowingly publish on the drugstore.com Site, any content that is contrary to law or false or misleading in any material respect. Any content
that either party reasonably determines to be contrary to law or false or misleading in any material respect shall be removed, upon notice from the determining party, as soon as practicable by the offending party. After such removal, the parties may
bring the dispute to the advertising liaisons for immediate resolution. 
 5.3 Rite Aid shall have final approval regarding any
representations made relating to the quality of Rite Aid pharmacy and Rite Aid pharmacist services with respect to LPU services offered by Rite Aid. 
 Section 6. Technology License and Integration 
  

	 	6.1	License to Technology 

 6.1.1
Rite Aid hereby grants to drugstore.com, and its wholly owned Affiliates, a royalty-free, worldwide, nonexclusive license (without any right to transfer or sublicense) to use, copy, publicly display, publicly perform, and create Derivatives
of the Rite Aid Technology and Rite Aid Technology Derivatives made by Rite Aid for use in connection with the drugstore.com business. The foregoing license grant is subject to any limitations imposed by Third Parties on Rite Aid and the
terms and conditions of this Agreement, including the exclusivity provisions set forth in Section 4. 
  

 6 

 6.1.2 drugstore.com hereby grants to Rite Aid, and its wholly owned
Affiliates, a royalty-free, worldwide, nonexclusive license (without any right to transfer or sublicense) to use, copy, publicly display, publicly perform, and create Derivatives of the Rite Aid Technology Derivatives made by drugstore.com for use
in connection with the Rite Aid business. The foregoing license grant is subject to any limitations imposed by Third Parties on drugstore.com and the terms and conditions of this Agreement, including the exclusivity provisions set forth in
Section 4. 
  

	 	6.2	License to Trademarks 

 6.2.1
drugstore.com hereby grants to Rite Aid and any of its wholly owned Affiliates a non-exclusive, royalty-free, worldwide license in all jurisdictions in which drugstore.com has any rights to use, reproduce, distribute and display the drugstore.com
Trademarks in connection with Rite Aid’s rights and obligations under this Agreement. 
 6.2.2 Rite Aid hereby
grants to drugstore.com and any of its wholly owned entities a non-exclusive, royalty-free, worldwide license in all jurisdictions in which Rite Aid has any rights to use, reproduce, distribute and display the Rite Aid Trademarks in connection with
drugstore.com’s rights and obligations under this Agreement. 
 6.2.3 Each party shall have the right to exercise
quality control over the use of its Trademarks by the other party to the degree necessary, in the sole opinion of the owner of such Trademarks, to maintain the validity and enforceability of such Trademarks and to protect the goodwill associated
therewith. Each party shall, in its use of the other’s Trademarks, adhere to a level of quality at least as high as that used by such party in connection with its use of its own Trademarks. If the owner of a Trademark, in its reasonable
opinion, finds that use of such Trademark by the other party materially threatens the goodwill of such Trademark, the user of such Trademark shall, upon notice from the owner, immediately, and no later than ten (10) business days after receipt
of such owner’s notice, take all measures reasonably necessary to correct the deviation(s) or misrepresentation(s) in, or misuse of, the applicable Trademark. 
 6.2.4 Each party shall use the other’s Trademarks in accordance with sound trademark and trade name usage principles and in
compliance with all applicable laws and regulations of the United States (including all laws and regulations relating to the maintenance of the validity and enforceability of such Trademarks) and shall not use the Trademarks in any manner that might
tarnish, disparage, or reflect adversely on the Trademarks or the owner of such Trademarks. Each party shall use, in connection with the other’s Trademarks, all legends, notices and markings required by law. No party may materially alter the
appearance of another’s Trademarks in any advertising, marketing, distribution, or sales materials, or any other publicly distributed materials without the prior written consent of the other party. 
  

	 	6.3	Access to Rite Aid Technology 

  

 7 

 6.3.1 Rite Aid will provide drugstore.com with user identifications and passwords
on an as-needed basis for the purpose of filling prescriptions for Pharmaceutical Products. All use of the user identifications, passwords and Rite Aid Technology shall be subject to Rite Aid’s then-current privacy, data access, and other
applicable policies. The user identifications and passwords shall only be used to perform the services described herein at the Rite Aid Pharmacy. 
 6.3.2 As reasonably requested by drugstore.com, Rite Aid will provide to drugstore.com copies of the Rite Aid Technology, or necessary portions thereof, in such manner as mutually agreed upon by the parties for
use by drugstore.com in accordance with the terms of this Agreement and for no other reason whatsoever. 
 6.3.3 The
parties will provide to each other updated copies, if any, of the Rite Aid Technology and the Rite Aid Technology Derivatives on a periodic basis when available, in such manner and at such times as mutually agreed upon by the parties, for use by the
parties in accordance with the terms of this Agreement. 
  

	 	6.4	Reservation of Rights 

 6.4.1
Rite Aid reserves ownership of the Rite Aid Technology. Except as specifically authorized or granted hereunder, no right, title or interest in, to or under any of the Rite Aid Technology is granted, created, assigned or otherwise transferred to
drugstore.com pursuant to or by virtue of this Agreement. 
 6.4.2 As between Rite Aid and drugstore.com,
Rite Aid shall own all Rite Aid IPR. 
 6.4.3 As between Rite Aid and drugstore.com, drugstore.com shall
own all drugstore.com IPR. 
 6.4.4 Notwithstanding the provisions of Sections 6.4.2 and 6.4.3, the ownership of a
Derivative shall not in itself convey any ownership or exploitation rights in the underlying work from which the Derivative was created. 
 6.4.5 During and after the term of this Agreement, each party shall, at the other party’s expense, perform any actions and execute any documents necessary to perfect the other party’s title in its
IPR. 
  

	 	6.5	Technology Integration and Transition of LPU 

 The
parties agree to use commercially reasonable efforts to ensure a seamless transition of the LPU services from drugstore.com to Rite Aid. Thereafter, the parties agree to work cooperatively to support the technology necessary for Rite Aid’s
provision of LPU. 
  

 8 

 Section 7. Representations and Warranties 
  

	 	7.1	Representations and Warranties of drugstore.com 

 7.1.1 drugstore.com hereby represents and warrants to Rite Aid: 
 (a)
Authorization. drugstore.com is an Affiliate of drugstore.com, inc., and that all corporate action on the part of drugstore.com, its officers, directors and stockholders necessary for the authorization, execution and delivery of this
Agreement, and the performance of all obligations of drugstore.com hereunder has been taken, and this Agreement, when executed and delivered by drugstore.com, will constitute a valid and legally binding obligation of drugstore.com, enforceable
against drugstore.com in accordance with its terms except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights
generally, as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 
 (b) Intellectual Property. To its knowledge, drugstore.com owns or possesses sufficient legal rights to all IPR necessary for its business as now conducted without any conflict with, or infringement of, the rights of others.
drugstore.com has not received any written communications alleging that any drugstore.com technology or drugstore.com Trademarks have violated or would violate any of the IPR of any Third Party. drugstore.com is not aware that any of its employees
is obligated under any contract or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with such employee’s ability to promote the interests of drugstore.com or that would
conflict with drugstore.com’s business. Neither the execution, delivery or performance of this Agreement, nor the carrying on of drugstore.com’s business as now conducted by the employees of drugstore.com, will, to drugstore.com’s
knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now obligated. drugstore.com does not believe it is or
will be necessary to use any inventions of any of its employees (or persons it currently intends to hire) made prior to their employment by drugstore.com. 
 (c) Compliance with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated thereby will not result in any violation of or be in
conflict with or constitute, with or without the passage of time and giving of notice, a default under any provision of drugstore.com’s or any of 

  

 9 

 
its Affiliates’ charter or bylaws or any instrument, judgment, order, writ, decree or contract to which drugstore.com or any of its Affiliates is a
party or by which drugstore.com or any of its Affiliates is bound, or any provision of any federal or state statute, rule or regulation applicable to drugstore.com or any of its Affiliates, the effect of which would have a material adverse effect on
the ability of drugstore.com or any of its Affiliates to perform its obligations under this Agreement or result in the creation of any lien, charge or encumbrance upon any assets of drugstore.com or any of its Affiliates. 
 (d) NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, DRUGSTORE.COM MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND
WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY GOODS OR SERVICES TO BE PROVIDED UNDER THIS AGREEMENT, OTHER THAN
THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. 
  

	 	7.2	Representations and Warranties of Rite Aid 

 7.2.1 Rite Aid hereby represents and warrants to drugstore.com: 
 (a) Authorization. Rite Aid is an
Affiliate of Rite Aid Corporation and that all corporate action on the part of Rite Aid, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, and the performance of all obligations of
Rite Aid hereunder has been taken, and this Agreement, when executed and delivered by Rite Aid, will constitute a valid and legally binding obligation of Rite Aid, enforceable against Rite Aid in accordance with its terms except as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally, as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies. 
 (b) Intellectual Property. To its knowledge, Rite Aid
owns or possesses sufficient legal rights to all IPR necessary for its business as now conducted without any conflict with, or infringement of, the rights of others. Rite Aid has not received any written communications alleging that any Rite Aid
Technology or Rite Aid Trademarks have violated or would violate any of the IPR of any Third Party. Rite Aid is not aware that any of its employees is obligated under any contract or other agreement, or subject to any judgment, decree or order of
any court or administrative 

  

 10 

 
agency, that would interfere with such employee’s ability to promote the interests of Rite Aid or that would conflict with Rite Aid’s business.
Neither the execution, delivery or performance of this Agreement, nor the carrying on of Rite Aid’s business as now conducted by the employees of Rite Aid, will, to Rite Aid’s knowledge, conflict with or result in a breach of the terms,
conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now obligated. Rite Aid does not believe it is or will be necessary to use any inventions of any of its employees (or
persons it currently intends to hire) made prior to their employment by Rite Aid. 
 (c) Compliance with Other
Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby will not result in any violation of or be in conflict with or constitute, with or without the passage of time and
giving of notice, a default under any provision of Rite Aid’s or any of its Affiliates’ charter or bylaws or any instrument, judgment, order, writ, decree or contract to which Rite Aid or any of its Affiliates is a party or by which Rite
Aid or any of its Affiliates is bound, or any provision of any federal or state statute, rule or regulation applicable to Rite Aid or any of its Affiliates, the effect of which would have a material adverse effect on the ability of Rite Aid or any
of its Affiliates to perform its obligations under this Agreement or result in the creation of any lien, charge or encumbrance upon any assets of Rite Aid or any of its Affiliates. 
 (d) NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, RITE AID MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND
WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY GOODS OR SERVICES TO BE PROVIDED UNDER THIS AGREEMENT, OTHER THAN
THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. 
 Section 8. Indemnification 
  

	 	8.1	Indemnification 

 Each party (the
“Indemnifying Party”) shall indemnify and hold harmless the other and its divisions, its Affiliates and its officers, directors, employees, representatives and agents (the “Indemnified Parties”) from and against
(i) any and all liabilities, suits, costs, judgments, penalties, expenses, obligations, losses and damages arising from or related to claims or actions made by a Third Party, including any obligation or liability 

  

 11 

 
that may be imposed on any of the Indemnified Parties as a matter of law, and constituting, or in any way based on, resulting from or arising out of
(1) any breach or alleged breach by the Indemnifying Party of any representation, warranty, agreement or covenant made by the Indemnifying Party in this Agreement or (2) any gross negligence or willful misconduct by the Indemnifying Party,
and (ii) any cost or expense (including legal fees and out-of-pocket expenses) reasonably incurred by any of the Indemnified Parties (and their counsel) in investigating, preparing for, defending against or otherwise taking any action in
connection with any of the foregoing. 
  

	 	8.2	Procedure 

 Subject to the provisions of
Section 9, if any claim, demand, assessment or liability or cost incidental thereto (collectively, an “Indemnified Claim”), is asserted against an Indemnified Party in respect of which the Indemnified Party proposes to demand
indemnification from the Indemnifying Party pursuant to Section 8.1, such Indemnified Party will promptly notify the Indemnifying Party in writing. No failure of an Indemnified Party to so notify the Indemnifying Party shall relieve the
Indemnifying Party from the obligation to indemnify the Indemnified Party unless and to the extent the Indemnifying Party is actually prejudiced by such failure. Such Indemnified Party will accord the Indemnifying Party the opportunity to assume
entire control for the defense, compromise or settlement of any such Indemnified Claim through its own counsel and at its own expense; provided that no such compromise or settlement shall include any non-monetary terms and conditions applicable to
such Indemnified Party without the consent of the Indemnified Party; and provided further, that the Indemnified Party may retain its own counsel at its own expense (the Indemnifying Party shall only be liable for the cost of one such counsel for all
Indemnified Parties) if (i) the Indemnifying Party, within thirty (30) days after notice of any Indemnified Claim, fails to assume the defense of such Indemnified Claim or (ii) the representation of both the Indemnifying Party and the
Indemnified Party would, in the reasonable judgment of the parties, be inappropriate due to actual or potential conflicting interests between them. If the Indemnifying Party does not assume entire control of the defense, compromise or settlement of
such Indemnified Claim, the Indemnified Party may compromise or settle any such Indemnified Claim. drugstore.com and Rite Aid each agrees to cooperate fully with respect to the defense of any Indemnified Claim. 
 Section 9. Infringement Claims 
  

	 	9.1	Legal Action for Infringement of IPR 

 9.1.1 Each party reserves any and all rights to commence, prosecute, compromise and settle any claim, action or proceeding for infringement, unfair competition, unauthorized use, misappropriation or violation of any of its IPR by any
Third Party, but shall not have any obligation to do so. Each party will keep the other party apprised of the status of any such claim, action or proceeding. 
  

 12 

 9.1.2 No party shall have the right to commence or prosecute any legal action with
regard to the IPR of the other party, without such other party’s prior written consent in such other party’s sole discretion. 
 9.1.3 If either party becomes the subject of a claim, action or proceeding for infringement, unfair competition, unauthorized use, misappropriation or violation of any IPR of a Third Party as a result of its
use of the other party’s IPR pursuant to this Agreement, then the party owning such IPR shall upon the request of such other party defend the requesting party from and against such claim, action or proceeding; provided that the requesting party
shall provide such assistance in defense of the claim, action or proceeding as the owning party may request and shall comply with any settlement or court order made in connection with the claim, action or proceeding (e.g., relating to the future use
of any infringing IPR); and provided further that, notwithstanding the foregoing, the requesting party shall indemnify the owning party from and shall pay any and all damages, liabilities, costs and expenses (including reasonable attorneys fees)
incurred by the owning party or otherwise arising out of such claim, action or proceeding to the extent related to the requesting party’s use of the owning party’s IPR. In any case, the requesting party shall be entitled to participate in
the defense of any such claim, action or proceeding, at its own cost, with counsel of its choice. 
 Section 10. Resolution of Disputes

  

	 	10.1	General 

 If any dispute arises between the parties
relating to this Agreement, each party will follow the dispute resolution procedures set forth in this Section 10 prior to initiating any litigation or pursuing other available remedies unless otherwise agreed in writing by the parties at the
time the dispute arises. Notwithstanding the foregoing, any party may commence litigation without having first complied with the provisions of this Section 10 if such commencement occurs within thirty (30) days prior to the date after
which the commencement of litigation would be barred by any statute of limitations, statute of repose or other law, rule, regulation, or order of similar import or in order to request injunctive or other equitable relief necessary to prevent
irreparable harm. In such event, the parties will (except as may be prohibited by judicial order) nevertheless continue thereafter to follow the procedures set forth in this Section 10. 
  

	 	10.2	Initiation of Procedures 

 If a party seeks to
initiate the procedures under this Section 10, such party will give written notice thereof to the other party. Such notice will (i) state that it is a notice initiating the procedures under this section, (ii) describe briefly the
nature of the dispute and the initiating party’s claim or position in connection with the dispute, and (iii) identify an individual with authority to settle the dispute on such party’s behalf. Within ten (10) days after receipt
of any notice under this Section 10.2, the receiving party will give the initiating party written notice that describes briefly the receiving party’s claims and positions in connection with the dispute and identifies an individual with the
authority to settle the dispute on behalf of the receiving party. 
  

 13 

	 	10.3	Pre-Litigation Discussion 

 The parties will cause
the individuals identified in their respective notices under Section 10.2 to promptly make such investigation of the dispute as such individuals deem appropriate. Promptly and in no event later than ten (10) days after the date of the
initiating party’s notice under Section 10.2, such individuals will commence discussions concerning resolution of the dispute. If the dispute has not been resolved within 30 days after commencement of such discussions, then any party may
request that the other party make its senior executives, as designated by such other party, available to discuss resolution of such dispute. Each party will cause its senior executives to meet together with the other party’s senior executives,
as designated by such party, to discuss such dispute at a mutually agreed upon time within 15 days after a party makes such request. If the dispute has not been resolved within 15 days after the senior executives of the parties have first met, then
any party may request that the other party make its president or CEO available to discuss resolution of such dispute. Each party will cause its president or CEO to meet together with the other party’s president or CEO to discuss such dispute at
a mutually agreed upon time within 15 days after a party makes such request. If the dispute has not been resolved within 15 days after the presidents or CEOs of the parties have first met, then any party may request that the other party make an
independent director available to discuss resolution of such dispute. “Independent Director” means any director that is neither an employee of, nor an outside provider of services to, a party. Each party will cause its Independent
Director to meet together with the other party’s Independent Director to discuss such dispute at a mutually agreed upon time within ten (10) days after a party makes such request. If the Independent Directors do not resolve the dispute
within five (5) days of their first meeting, the parties shall submit the dispute for non-binding mediation to a mutually agreed upon mediator or mediation firm. The parties will use their best efforts to cause the mediator to resolve the
dispute within 15 days of its submission thereto. If the mediator is unable to resolve the dispute within such time period, any party may submit the dispute to litigation. 
 Section 11. Breach; Termination; Extension 
  

	 	11.1	Breach by Rite Aid 

 11.1.1
In the event of a material breach by Rite Aid of any of its material obligations under this Agreement, which breach Rite Aid does not cure within sixty (60) days after drugstore.com gives Rite Aid written notice thereof, drugstore.com will
have any and all of the following rights: 
 (i) the right to terminate this Agreement; 
 (ii) the right to seek indemnification pursuant to Section 8; and 
 (iii) the right to sue for breach. 
  

 14 

 11.1.2 All of the foregoing rights are subject to the provisions of
Section 12.6 and 12.7. 
  

	 	11.2	Breach by drugstore.com 

 11.2.1
In the event of a material breach by drugstore.com of any of its material obligations under this Agreement , which breach drugstore.com does not cure within sixty (60) days after Rite Aid gives drugstore.com written notice thereof, Rite Aid
shall have any and all of the following rights: 
 (i) the right to terminate this Agreement; 
 (ii) the right to seek indemnification pursuant to Section 8; and 
 (iii) the right to sue for breach. 
 11.2.2 All of the foregoing rights are subject to
the provisions of Section 12.6 and 12.7. 
  

	 	11.3	Termination 

 This Agreement will terminate upon the
earliest of (i) expiration of the Term and (ii) a termination pursuant to section 11.1 or 11.2. Sections 6.4, 8 (with respect to claims, damages or other losses related to or arising from events occurring prior to termination), 11 and 12
shall survive any termination of this Agreement. In addition, no termination shall release a party from liability for breaches occurring prior to such termination. 
  

	 	11.4	Consequential Damages; Limitation of Liability 

 In
no event will either party have any liability, whether based in contract, tort (including, but not limited to, negligence), warranty or other legal or equitable grounds for any loss of interest, profit or revenue by the other party or for any
consequential, indirect, incidental, special, punitive or exemplary damages suffered by the other party arising from or related to this Agreement. 
  

	 	11.5	Extension 

 The parties agree that this Agreement
automatically extends for one (1) additional one (1) year period unless either party provides the other with notice of its intent to not renew at least ninety (90) days prior to the end of the Term. 
  

 15 

 Section 12. Miscellaneous 
  

	 	12.1	Relationship 

 The parties are independent
contractors under this Agreement. Each party acknowledges and agrees that it is not and will not be during the Term an employee or an agent of the other party. Nothing in this Agreement will be deemed to constitute, create, give effect to or
otherwise recognize a joint venture, partnership, franchise or business entity of any kind. Nothing in this Agreement will be construed as providing for the sharing of profits or losses arising out of the efforts of the parties hereto. 

 

	 	12.2	Assignment; Sale of Assets or Capital Stock 

 This
Agreement shall be binding upon and inure to the benefit of the parties hereto, and the legal representatives, successors in interest and permitted assigns, respectively, of each such party. This Agreement shall not be assigned in whole or in part
by any party without the prior written consent of the other party, such consent not to be unreasonably withheld; provided, however, that a party may, without consent of the other party, assign this Agreement to an Affiliate of the assignor, or to an
entity acquiring all or substantially all the assets or capital stock of the assignor due to merger, acquisition, consolidation or otherwise so long as (a) the assignor remains liable for the full and faithful performance of its obligations
hereunder, (b) such Affiliate or successor in writing assumes all of the obligations of the assignor under this Agreement and agrees to comply with the terms set forth in this Agreement, and (c) a copy of the assignment is provided to the
non-assigning party. The parties’ respective rights and obligations under this Agreement shall survive any transaction pursuant to which a Third Party acquires all or substantially all the assets or capital stock of either party, whether due to
merger, acquisition, consolidation or otherwise. 
  

	 	12.3	Notices 

 All notices, requests, demands,
applications, services of process, and other communications that are required to be or may be given under this Agreement shall be in writing and shall be deemed to have been duly given if sent by telecopy or facsimile transmission, answer back
requested, or delivered by courier or mailed, certified first class mail, postage prepaid, return receipt requested, to the parties to this Agreement at the following addresses: 
  

			
	If to Rite Aid:	  	 Rite Aid Hdqtrs. Corp.
 30 Hunter Lane
 Camp Hill, PA 17011
 Attn: General Counsel
 Fax: 717-760-7867

  

 16 

			
	If to drugstore.com:	  	 DS Pharmacy, Inc.
 411 108th Avenue, NE
 Suite 1400
 Bellevue, WA 98004
 Attn: General Counsel
 Fax: 425-372-3808

 or to such other address as the party shall have furnished to the other party by notice given in accordance with
this Section 12.3. Such notice shall be effective (i) if delivered in person or by courier, upon actual receipt by the intended recipient, or (ii) if sent by telecopy or facsimile transmission, on the date of transmission unless
transmitted after normal business hours, in which case on the following date, or (iii) if mailed, upon the date of first attempted delivery. 
  

	 	12.4	Waiver 

 No provision of this Agreement shall be
deemed to be waived and no breach excused unless such waiver or consent shall be in writing and signed by the party that is claimed to have waived or consented. The failure of a party at any time, or from time to time, to require performance by the
other party of any provision hereof shall in no way affect the rights of such party thereafter to enforce the same nor shall the waiver by a party of any breach of any provision hereof by the other party constitute a waiver of any succeeding breach
of such provision, or a waiver of any provision itself, or a waiver of any other provisions hereof. 
  

	 	12.5	Severability 

 This Agreement will be enforced to
the fullest extent permitted by applicable law. If for any reason any provision of this Agreement is held to be invalid or unenforceable to any extent, then: (a) such provision will be interpreted, construed or reformed to the extent reasonably
required to render the same valid, enforceable and consistent with the original intent underlying such provision; (b) such provision will be void to the extent it is held to be invalid or unenforceable; (c) such provision will remain in
effect to the extent that it is not invalid or unenforceable; and (d) such invalidity or unenforceability will not affect any other provision of this Agreement or any other agreement between the parties. 
  

	 	12.6	Remedies 

 Except as otherwise expressly provided in
this Agreement, each and all of the rights and remedies provided in this Agreement, and each and all of the remedies allowed at law and in equity, will be cumulative, and the exercise of one right or remedy will not be exclusive of the right to
exercise or resort to any and all other rights or remedies provided in this Agreement or at law or in equity. 
  

 17 

	 	12.7	Injunctive Relief 

 The parties acknowledge that a
material breach of this Agreement would cause irreparable harm, the extent of which would be difficult to ascertain. Accordingly, they agree that, in addition to any other legal remedies to which the non-breaching party may be entitled, such party
will be entitled to obtain immediate injunctive relief in the event of a material breach of this Agreement. 
  

	 	12.8	Governing Law 

 This Agreement will be governed by
and construed according to the laws of the State of Delaware without regard to its choice of law provisions. The parties consent to the jurisdiction of such courts and waive any right to assert that any such court constitutes an inconvenient or
improper forum. 
  

	 	12.9	Publicity 

 Neither party shall, without the
approval of the other, make any press release or other public announcement concerning the transactions contemplated by this Agreement, except as and to the extent that any such party shall be so obligated by law or by the rules, regulations or
policies of any national securities exchange or association or governmental entity, in which case the other party shall be advised and the parties shall use their best efforts to cause a mutually agreeable release or announcement to be issued;
provided, however, that the parties hereby acknowledge and agree that communications among employees of the parties and their attorneys, representatives and agents necessary to consummate the transactions contemplated hereby shall not be deemed a
public announcement for purposes of this Section 12.9. Upon the execution and delivery of this Agreement, the parties hereto will cooperate in respect of the immediate issuance of a mutually acceptable press release relating to the transactions
contemplated by this Agreement. 
  

	 	12.10 	Entire Agreement 

 All Exhibits and Schedules to
this Agreement are incorporated in and constitute a part of this Agreement. This Agreement, including the Exhibits and Schedules hereto, each as amended from time to time, constitute the entire understanding between the parties in relation to the
subject matter hereof and supersede all prior discussions, agreements and representations related to this subject matter, whether oral or written and whether or not executed by a party. Unless otherwise provided in this Agreement, no modification,
amendment or other change may be made to this Agreement or any part thereof unless reduced to writing and executed by authorized representatives of all parties. 
  

 18 

	 	12.11 	Counterparts 

 This Agreement may be executed in two
or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
  

	 	12.12 	Titles and Subtitles 

 The titles and subtitles used
in this Agreement and in the Exhibits and Schedules hereto are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  

	 	12.13 	Force Majeure 

 Neither party shall be responsible
for a failure to meet its obligations under this Agreement to the extent caused by the following: (i) materially inaccurate data submitted by the other party; (ii) any failure by the other party to meet its obligations stated in this
Agreement; (iii) any failure of equipment, facilities or services not controlled or supplied by such party; or (iv) failure(s) caused by acts of God, acts of nature, riots and other major civil disturbances, strike by such party’s
personnel, sabotage, injunctions or applicable laws or regulations, in each case without breach by such party of any obligations under this Agreement with regard to either such event or such failure. Rite Aid or drugstore.com, as applicable, agrees
to use its commercially reasonable efforts to restore performance of its obligations under this Agreement as soon as reasonably practicable following any such event. 
  

	 	12.14 	Confidentiality 

 The parties intend for the terms
set forth in this Agreement to be confidential and subject to the terms of the Mutual Confidentiality Agreement dated of even date herewith. 
 [Signature Page Follows] 
  

 19 

 In witness whereof, the parties have duly entered into this Amended and Restated Main Agreement as of the
date first written above. 
  

									
	RITE AID HDQTRS. CORP.	 		 	DS PHARMACY, INC.
					
	By:	 	/s/ James J. Comitale	 		 	By:	 	/s/ Dawn Lepore
	Name:	 	James J. Comitale	 		 	Name:	 	Dawn Lepore
	Title:	 	 Vice President and Assistant
 General
Counsel
	 		 	Title:	 	Chief Executive Officer
					
	Address:	 	 30 Hunter Lane
 Camp Hill, PA 17011
	 		 	Address:	 	 411 108th Ave. NE
 Suite 1400
 Bellevue, WA 98004

  

 20 

 CONSENT AND GUARANTEE 
 Rite Aid Corporation hereby consents to the amendment and restatement of the Main Agreement in its entirety as set forth herein and guarantees to drugstore.com, inc. and its Affiliates the prompt, punctual and full
performance of the obligations of Rite Aid Hdqtrs. Corp. under the Amended and Restated Main Agreement. 
  

			
	RITE AID CORPORATION
		
	By:	 	/s/ James J. Comitale
	Name:	 	James J. Comitale
	Title:	 	 Vice President and Assistant
 General
Counsel

		
	Address:	 	 30 Hunter Lane
 Camp Hill, PA
17011

 CONSENT AND GUARANTEE 
 drugstore.com, inc. hereby consents to the amendment and restatement of the Main Agreement in its entirety as set forth herein and guarantees to Rite Aid Hdqtrs. Corp., and its Affiliates the prompt, punctual and full
performance of the obligations of DS Pharmacy, Inc. under the Amended and Restated Main Agreement. 
  

			
	DRUGSTORE.COM, INC.
		
	By:	 	/s/ Dawn Lepore
	Name:	 	Dawn Lepore
	Title:	 	Chief Executive Officer
		
	Address:	 	 411 108th Ave. NE
 Suite 1400
 Bellevue, WA 98004

  

 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]